Webcast: Global Advancements in Prostate Cancer: Best Practices in Hormonal Therapy (2022) - English

Global Advancements in Prostate Cancer: Best Practices in Hormonal Therapy (2022) is an exciting new global educational initiative featuring a Moderator and two other subject matter experts in an interactive, interview-style presentation and discussion.  

Based on the documented need from the AUA Phase IV Advanced Prostate Cancer Global Needs Assessment, the AUA has produced this new series of educational offerings for urologists and the urologic care team focused on the advancements in treating patients with advanced prostate cancer. This course will address the latest developments in advanced prostate cancer disease states mHSPC, M0 CRPC and M1 CRPC with a focus on patient selection/identification, mechanisms of action, side effects, and sequencing, advances in imaging with recent FDA approvals of novel PSMA - PET scans, patient outcomes and AUA Clinical Guideline recommendations. 

The webcast will be made available on AUAUniversity and AUA's YouTube channel. Additionally, the course will be released as part of AUA's podcast series. Learners will also be provided with links to access additional resources including the AUA’s clinical guidelines discussed during the virtual courses and associated patient resources.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

  • AstraZeneca
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Merck

Target Audience

  • Urologists
  • Residents

Learning Objectives

After participating in this educational series, participants will be able to:

  1. List advanced prostate cancer disease states (mHSPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice.
  2. Identify available approved therapies and outcomes for each of these disease states: MHSPC, M0 CRPC, M1 CRPC.
  3. Demonstrate the appropriate indications, unique mechanisms of action and side effects of new and existing androgen axis agents, immunotherapies, chemotherapeutic agents and bone targeted therapies.
  4. Explain the sequencing of available therapies, as well as identifying adverse events that might occur when considering combination therapy.
  5. Review the evidence and outcomes on androgen deprivation treatment alone and in combination as outlined in the newly released Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
04/13/2022
Course expires: 
04/13/2023
Rating: 
0

Education Council Disclosures

 Education Council Disclosures 2021

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures 2021

Faculty Disclosures

PDF icon Best Practices in Hormonal Therapy Faculty Disclosures

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 1.00 hours

Release Date: April, 2022
Expiration Date: April, 2023

ACCREDIDATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group. 
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning 
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

 The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

CONSENT TO USE OF PHOTOGRAPHIC IMAGES:

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

SPECIAL ASSISTANCE/ DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.